Financings Of The Fortnight Ponders A Post-Euro Financing Environment
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus news on recent financings by TopiVert, Dendreon, Inhibitex and Celsion.
You may also be interested in...
Dendreon Says Provenge On Track For Steady Growth, Downplays Rising Competition
In an earnings call Nov. 2, Dendreon reported Q3 growth in sales and uptake of its prostate cancer active immunotherapy Provenge despite near term pressures.
Celsion Transitioning From Development To Commercial-Stage Company; Relocates To N.J.
Biotech's primary liver cancer drug ThermoDox should produce pivotal Phase III data in the next 12 to 14 months.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”